Zhai Jinghui, Zhang Yue, Ma Shuyue, Zhang Yingli, Jin Miao, Yan Huiyu, Zhang Sixi
Department of Clinical Pharmacy, The First Hospital of Jilin University, Changchun, Jilin, China.
School of Pharmaceutical Science, Jilin University, Changchun, Jilin, China.
Front Cell Dev Biol. 2025 Aug 15;13:1604539. doi: 10.3389/fcell.2025.1604539. eCollection 2025.
Drug-induced brain injury (DIBI) results from toxicity, interactions or misuse and is increasingly linked to gut-microbiota dysbiosis operating via the gut-brain axis. Disturbed microbial balance drives three core mechanisms-oxidative stress, neuroinflammation and metabolic dysfunction-leading to blood-brain barrier leakage, neuronal loss and cognitive impairment; antibiotics, antineoplastics and psychoactive drugs further promote bacterial translocation and systemic inflammation. Microbial metabolites and neurotransmitters also mediate post-injury anxiety and depression. Restoring microbial equilibrium with probiotics, prebiotics or microbiota transplantation attenuates these pathways and offers a promising therapeutic strategy for DIBI.
药物性脑损伤（DIBI）由毒性、相互作用或滥用引起，并且越来越多地与通过肠-脑轴起作用的肠道微生物群失调相关。微生物平衡紊乱驱动氧化应激、神经炎症和代谢功能障碍这三个核心机制，导致血脑屏障渗漏、神经元丢失和认知障碍；抗生素、抗肿瘤药和精神活性药物进一步促进细菌易位和全身炎症。微生物代谢产物和神经递质也介导损伤后的焦虑和抑郁。用益生菌、益生元或微生物群移植恢复微生物平衡可减弱这些途径，并为药物性脑损伤提供了一种有前景的治疗策略。
